Browsing: Stock

Medtronic plc (NYSE:MDT) and Tenet Healthcare Corporation (NYSE:THC) offer investors two very different healthcare growth stories. Medtronic’s (NYSE:MDT) thesis rests on whether a new generation of medical devices can produce a durable turnaround across its enormous portfolio. Tenet (NYSE:THC), meanwhile, is generating stronger earnings by improving hospital profitability and focusing its ambulatory business on higher-acuity…

JS Global Lifestyle stock closed at HK$1.575 after a solid run in recent weeks, yet the real story sits in the profit line. H1 2026 delivered basic earnings per share of US$0.003 and net income of US$9.419 million, keeping the recent turn back to profitability intact but at a modest level for a global home…

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge

Atour Lifestyle Holdings stock barely blinked after its Q2 report, inching up about 1.5% even as the company posted another hefty jump in revenue and profit. Investors came in with a growth story already in mind, backed by a relatively low P/E and strong trailing earnings momentum, so a clean headline beat alone was never…

Eli Lilly is one of the most popular names today in America’s weight-loss and diabetes drug market. Its drugs delivered an average weight loss of 28.3% in a Phase 3 trial, approaching results historically associated with bariatric surgery and potentially giving Lilly another major product after the success of Mounjaro

Shares of Ultragenyx PharmaceuticalRARE are rising in premarket trading today following the FDA’s accelerated approval of DTX-401, an AAV8 gene therapy for glycogen storage disease type Ia (GSDIa)

Eli Lilly shares rose 3.6% on Tuesday after completing a previously announced deal with AlzeCure Pharma for its preclinical Alzheimer’s drug candidate ACD680 — finalizing the initial transaction with a $10 million upfront payment — and entering a separate collaboration with OmniAb for an ion channel program, adding yet another chapter to what is becoming…

Shares of Ultragenyx Pharmaceutical (RARE) fell for the second consecutive day on Tuesday ahead of a closely watched U.S. Food and Drug Administration decision on its gene therapy slated for this weekend

Shares of inclusive gym franchise companyPLNTjumped 4.7% in the afternoon session after Morgan Stanley raised its price target to $51 from $47, according to MarketBeat. Morgan Stanley kept an Equal Weight rating. At about $50.56, the new $51 target implies less than 1% upside, so this is a valuation tweak, not a bullish rating change.…

Novo Nordisk (ISIN DK0062498333) stock is trading in the mid-$40s per American depositary receipt after closing at $44.89 on August 17, 2026, leaving the shares down 11.8% year-to-date compared with a level of $50.88 at the start of 2026. Per recent market data, the stock was changing hands at $44.89 at 3:58 p.m. ET on…